Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Mediwound Ltd Ord Sh

(NASDAQ: MDWD)
Add to Portfolio
-0.17 (-5.40%)
as of Nov 21, 2019

Last 2.98
Change -0.17 (-5.40%)
Open 3.10
Prev. Close 3.15
Today's Range
2.97
3.15
52wk Range
2.55
6.09
Volume 69,300
Avg Volume 39,075
Sector SIC-2833 Medicinal Chemicals & Botanical Products

Perfomance Comparison

Name Today 3-Month 1-Year
MDWD -5.40% -6.88% -48.62%
DJIA -0.20% +2.15% +13.50%
S&P 500 -0.16% +3.12% +17.12%

Key Statistics

Annual EPS 0.70
Dividend Yield 0.00%
P/E Ratio N/A
Market Capitalization, $K 84,530
Weighted Alpha -48.90
Standard Deviation -1.77
Profit Margin N/A
Beta 0.48

Growth Rates

YTD -26.60%
1-Year -49.49%
3-Year -43.24%
5-Year -49.66%

Opinion

Sell Hold Buy

Recent Headlines

MediWound (MDWD) Reports Q3 Loss, Tops Revenue

ZACKS - Thu Nov 14, 08:25AM EST
MediWound (MDWD) delivered earnings and revenue surprises of 15.38% and 92.80%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?(full story)
MDWD: 2.98 (-0.17)

Earnings Preview: MediWound (MDWD) Q3 Earnings

ZACKS - Thu Nov 07, 10:30AM EST
MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.(full story)
MDWD: 2.98 (-0.17)

MediWound to Report Third Quarter 2019 Financial

GlobeNewswire via COMTEX - Wed Nov 06, 08:00AM EST
MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial resu(full story)
MDWD: 2.98 (-0.17)

Vericel and MediWound Announce Initiation of U.S.

GlobeNewswire via COMTEX - Wed Oct 02, 07:30AM EDT
Vericel Corporation (NASDAQ: VCEL) and MediWound Ltd. (NASDAQ: MDWD) today announced initiation of the NexoBrid expanded access treatment protocol (NEXT) to treat burn patients with deep partial- and full-thickness burns in the U.(full story)
VCEL: 18.44 (-0.40), MDWD: 2.98 (-0.17)

NexoBrid(R) Highlighted in 39 Presentations at the

GlobeNewswire via COMTEX - Tue Sep 03, 08:01AM EDT
MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound care management, today announced a significant presence at the 18 European B(full story)
MDWD: 2.98 (-0.17)